|
Gastric Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study investigated the expression pattern and prognostic significance of HER-2 and RAB1A in gastric adenocarcinoma (CAG).
|
29552156 |
2018 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Similarly, silencing Rab1A with small interfering RNA also suppressed glioma cell growth and induced endoplasmic reticulum stress and apoptosis.
|
28443461 |
2017 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that DANCR/miR-634/RAB1A axis plays crucial roles in the progression of glioma, and DANCR might potentially serve as a therapeutic target for the treatment of glioma patients.
|
29301870 |
2018 |
|
Heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In multiple independent mouse lines, Rab1a overexpression caused cardiac hypertrophy that progressed in a time- and transgene dose-dependent manner to heart failure.
|
11739277 |
2001 |
|
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
Role for TBC1D20 and Rab1 in hepatitis C virus replication via interaction with lipid droplet-bound nonstructural protein 5A.
|
22491470 |
2012 |
|
HER2 gene amplification
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HER-2 and RAB1A protein expression was assessed by immunohistochemistry and cases with a 2+ score for HER-2 expression levels were subjected to fluorescence <i>in situ</i> hybridization to determine the HER-2 amplification status.
|
29552156 |
2018 |
|
Hormone refractory prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
By performing systematic biochemical and bioinformatical analyses, we identified two miR-221 targets, HECTD2 and RAB1A, which could mediate the development of CRPC phenotype in multiple prostate cancer cell lines.
|
23770851 |
2014 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, these findings extend our understanding of Rab1a in progression of ICC, and we found hypoxia/miR-212-3p/Rab1a pathway played important role for progression of ICC.
|
29672195 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33.
|
27693040 |
2016 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that miR-15b-5p induces ERS, apoptosis, and growth inhibition by targeting and suppressing Rab1A, acting as a tumor suppressor gene in HCC.
|
26023735 |
2015 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation.
|
27998765 |
2017 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Locally Recurrent Malignant Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with rectal cancer staged ypT4N0 were associated with higher locoregional recurrence and distant metastasis rates than those staged ypT1-2N1 in the current staging system.
|
30595556 |
2019 |
|
Machado-Joseph Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Increase in the levels of lysosomal-associated membrane protein 2 (LAMP-2) and of the endosomal markers (Rab7 and Rab1A) were observed in MJD patients relatively to controls.
|
29218765 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.
|
31485677 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Emerging evidence has verified that Rab1A plays an oncogenic role in several human malignancies including breast cancer, lung cancer, and hepatocellular carcinomas.
|
30058685 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Then, MTT cell proliferation, colony formation, cell invasion and wound healing assays were performed to characterize the function of RAB1A in the breast cancer cell lines.
|
28184936 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of Rab1A and its prognostic significance in human colorectal cancer.
|
30058685 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.
|
30896866 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
RAB1A acts as an oncogene in various cancers, and emerging evidence has verified that RAB1A is an mTORC1 activator in hepatocellular and colorectal cancer, but the role of RAB1A in breast cancer remains unclear.
|
28184936 |
2017 |
|
Malignant neoplasm of gastrointestinal tract
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the exact role of Rab1A in gastrointestinal cancers remains elusive.
|
31527621 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggested that Rab1A may be involved in the pathogenesis of human lung cancer in an mTOR- and MAPK-independent manner.
|
27902464 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (IHC) was performed to explore the association of Rab1A/p-S6K/Gli1 expression and prognosis in 117 GC tissue samples and adjacent normal tissues.
|
31038077 |
2019 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In recent years, the aberrant expression of RAB1A has been reported in a number of tumours, but its regulation in GC has not been extensively examined.
|
29552156 |
2018 |